Wednesday, Hall 5, 13:00-13:40

Long-term impact on clinical and safety outcomes in IBD when switching from IV to SC Infliximab

This promotional symposium is open to GB and NI Healthcare Professionals only and has been organised and funded by Celltrion Healthcare UK Ltd. Celltrion products will be discussed at this meeting.

The Celltrion symposium at BSG this year will examine the long-term impact on clinical and safety outcomes in IBD when switching from Intravenous (IV) infliximab to Subcutaneous (SC) infliximab, compared to maintaining Intravenous (IV) infliximab therapy.  Professor James Lindsay, Consultant Gastroenterologist at the Royal London Hospital, Barts Health NHS Trust, will both Chair and present the session.  For approximately 25 minutes, Prof Lindsay will present a comparative Real World data analysis of IV infliximab versus switching to SC infliximab during maintenance treatment in IBD patients.  This will then be followed by a chaired 15-minute question and answer session with the gathered audience in attendance.

Chair and Speaker: Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust, The Royal London Hospital.

This promotional symposium is open to GB and NI Healthcare Professionals only and has been funded by Celltrion Healthcare UK Ltd. Celltrion products will be discussed at this meeting.

13.00 – 13:25:  Speaker presentation: ‘Comparative Real World data analysis of IV- IFX versus switching to SC- IFX during maintenance treatment in IBD’ 
13.25 – 13.40:  Q&A session.
13.40 Close.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Celltrion Healthcare by calling: + 44 (0) 1753 983500.  

For Remsima® (infliximab) Prescribing information click the link below

  1. NI Prescribing information for Remsima® SC (infliximab)
  2. GB Prescribing information for Remsima® SC (infliximab)
  3. NI Remsima® IV(infliximab)100mg powder for concentrate for solution for infusion
  4. GB Prescribing information for Remsima® IV (infliximab)

Remsima® SC (infliximab) is indicated in:
Adult Crohn’s Disease (CD): Remsima is indicated for the treatment of moderately to severely active CD in adult patients who have not responded to a full and adequate course of, are intolerant of, or have medical contraindications to therapy with a corticosteroid and/or an immunosuppressant; and fistulising active CD in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy). Ulcerative Colitis (UC): Remsima is indicated for the treatment of moderately to severely active UC in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Only Remsima® IV is indicated in Paediatrics Crohn’s disease and Paediatric Ulcerative colitis.
Remsima® IV (infliximab) is indicated in:
Adult Crohn’s disease
Remsima is indicated for:
• treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
• treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).

Paediatric Crohn’s disease
Remsima is indicated for treatment of severe, active Crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy.

Ulcerative colitis
Remsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Paediatric ulcerative colitis
Remsima is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.

UK-REMS-24-00032 May 2024